January 21, 2020 10:37 AM EST
News Briefing

As­traZeneca scores or­phan sta­tus for PD-L1/CT­LA-4 com­bo; EMA OKs No­var­tis' MS drug Mayzent

ENDPOINTS

→ As­traZeneca gained an or­phan drug des­ig­na­tion for its com­bi­na­tion of Imfinzi and the CT­LA-4 drug treme­li­mum­ab for he­pa­to­cel­lu­lar car­ci­no­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

A service from the Financial Times